CREATE Medicines
PrivateLast Round
Series B
May 14, 2026
Total Funding Raised
$245M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
CREATE Medicines is a clinical-stage biotechnology company that develops mRNA-based in vivo cell therapies for the treatment of cancer, autoimmunity, and fibrosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CREATE Medicines Comparables
Compare CREATE Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stylus Medicine | 86% | |
| Aera Therapeutics | 85% | |
| Alaya.bio | 84% |
CREATE Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 14, 2026 | ||||
| Series A Extension | May 18, 2023 | ||||
| Series A | Jan 6, 2021 |
Key People
Founding team and executive leadership
CREATE Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Newpath Partners | Series B, Series A, Series A Extension |
| ARCH Venture Partners | Series A Extension, Series B |
| Hatteras Venture Partners | Series A, Series B, Series A Extension |
| Moore Strategic Ventures | Series A Extension |
| ARCH Venture Partners | Series A Extension |
| Alexandria Venture Investments | Series B, Series A Extension, Series A |
| Hatteras Investment Partners | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors increased 92% MoM.
- Jul 27, 2026
Grew 19% QoQ, from 37 to 44 employees.
CREATE Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about CREATE Medicines's valuation, stock price, and market status.
Is Myeloid Therapeutics a public or private company?
Myeloid Therapeutics is a private company.
What is the current stock price of Myeloid Therapeutics?
Myeloid Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Myeloid Therapeutics worth (valuation)?
Valuation information for Myeloid Therapeutics is not publicly available.
Can I buy Myeloid Therapeutics stock?
Myeloid Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Myeloid Therapeutics's last funding round?
Myeloid Therapeutics's most recent funding round was Series B on May 18, 2023.
Who are the main investors in Myeloid Therapeutics?
Key investors in Myeloid Therapeutics include Newpath Partners.
Will Myeloid Therapeutics IPO soon?
No public IPO plans have been announced for Myeloid Therapeutics.
How can I track Myeloid Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Myeloid Therapeutics's secondary market activity and sign up for updates.